Baxter has completed regulatory clearance for THERANOVA in Europe (CE marking), Australia and New Zealand, among other countries. It will be available in select countries in 2016, with additional launches planned for 2017. THERANOVA is not currently available in the United States.
For prescription only. For safe and proper use of THERANOVA, refer to the complete instructions in the Operator's Manual.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About Baxter
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Forward-Looking Statements
This release includes forward-looking statements concerning THERANOVA, one of Baxter’s dialysis membranes, including expectations regarding the planned launch of THERANOVA, its potential impact on patients and benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: actions of regulatory bodies and other governmental authorities; satisfaction of regulatory and other requirements; product quality or patient safety issues; changes in laws and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.
Baxter and Theranova are registered trademarks of Baxter International Inc.
____________
1 Boschetti-de-Fierro A, et al. MCO membranes: Enhanced selectivity in high-flux class. Sci Rep 2015; 5:18448.
2 Krause B, et al. Highly selective membranes for blood purification. Abstract accepted for Euromembrane Congress; Aachen (Germany) 2015. [Abstract E139].
3 Leypoldt K, et al; Clearance of Middle Molecules during Haemodialysis and Haemodiafiltration: New Insights. Nephrology Dialysis Transplantation (2012); 27 (12): 4245-4247. doi: 10.1093.
4 Tattersall and Ward; Online Haemodiafiltration: Definition, Dose Quantification and Safety Revisited; Nephrology Dialysis Transplantation (2013); 10.1093.
